Viela Bio, Inc.
(NASDAQ : VIE)

( )
VIE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.07%200.801.3%$462.93m
BIIBBiogen Inc.
0.09%223.211.3%$371.70m
GILDGilead Sciences, Inc.
-0.09%63.930.9%$362.66m
CELGCelgene Corporation
0.76%100.571.3%$359.89m
ILMNIllumina, Inc.
1.48%302.583.5%$282.38m
REGNRegeneron Pharmaceuticals, Inc.
0.81%300.772.6%$210.74m
EXASExact Sciences Corporation
2.19%92.5024.1%$193.04m
VRTXVertex Pharmaceuticals Incorporated
1.29%172.411.9%$181.51m
ALXNAlexion Pharmaceuticals, Inc.
0.92%99.252.0%$176.54m
AAgilent Technologies, Inc.
1.77%75.311.6%$166.98m
SRPTSarepta Therapeutics, Inc.
0.39%83.4814.6%$138.14m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.8710.2%$125.33m
BMRNBioMarin Pharmaceutical Inc.
1.29%67.364.3%$96.05m
ACADACADIA Pharmaceuticals Inc.
0.10%40.5213.4%$95.97m
INCYIncyte Corporation
0.46%76.122.5%$87.99m

Company Profile

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.